Advanced Therapy Medicinal Products Market Outlook:
Advanced Therapy Medicinal Products Market size was valued at USD 45.2 billion in 2025 and is likely to cross USD 175.06 billion by 2035, expanding at more than 14.5% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of advanced therapy medicinal products is assessed at USD 51.1 billion.
The growth of the market can be attributed to the increased prevalence of the genetic disorder. Drugs used in gene therapy are advanced therapy medicinal products that contain genes that have therapeutic, preventative, or diagnostic effects. Recombinant genes are inserted into the body to cure a number of illnesses, such as cancer, genetic problems, and chronic diseases. For instance, all over the world around 300 million people are living with a rare disease and it affects nearly 4% to 6% of the total world population.
In addition to these, factors that are believed to fuel the growth of the advanced therapy medicinal products market include higher adoption of gene therapy. Gene therapy is known to be one of the advanced therapy medicinal products. The therapy is used to treat the underlying genetic disorder by correcting the faulty gene in the body. In one study, 93 percent of respondents supported the use of gene therapy to treat Leber congenital amaurosis, an inherited form of blindness, while just 35 percent said it was certainly okay to use it to improve memory. Furthermore, advanced therapy medicinal products are used to replace or restore dopamine transmission in various parts of the nervous system. Therefore, increased cases of neurological ailment are anticipated the higher projection of the advanced therapy medicinal products market. According to the Pan American Health Organization’s 2019 statistics, around 7.5 million people are living with a neurological disorder and 533,172 deaths are due to the neurological condition.
